Loading clinical trials...
Loading clinical trials...
A Phase 2 Study Evaluating the Efficacy of Elacestrant in Patients With Estrogen Receptor Positive Uterine Sarcomas
Conditions
Interventions
Elacestrant
Locations
1
United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
April 15, 2026
Primary Completion Date
July 1, 2027
Completion Date
April 1, 2028
Last Updated
April 21, 2026
NCT01303094
NCT07269535
NCT01979393
NCT03493165
NCT03241745
NCT05881967
Lead Sponsor
Dana-Farber Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions